Review





Similar Products

96
Cell Signaling Technology Inc phospho smad2 3
Effects of ATL-III on TGF-β1-induced intracellular signaling in primary human corneal keratocytes. Primary human corneal keratocytes were treated with TGF-β1 (10 ng/mL) alone or in combination with ATL-III (50 or 100 µM) for 1 h. Representative Western blot images and corresponding densitometric analyses are shown for ( a ) <t>phosphorylated</t> <t>SMAD2/3</t> (p-SMAD2/3) and total SMAD2/3, ( b ) phosphorylated p38 MAPK (p-p38 MAPK) and total p38 MAPK, ( c ) phosphorylated AMPK (p-AMPK) and total AMPK, ( d ) phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2, and ( e ) phosphorylated NF-κB (p-NF-κB) and total NF-κB. Phosphorylated protein levels were normalized to their corresponding total protein levels and expressed relative to the untreated control group. n = 3 independent experiments. Statistical significance was determined by one-way ANOVA followed by Dunnett’s multiple-comparison test, with the TGF-β1-treated group used as the reference group for treatment comparisons. * p < 0.05, ** p < 0.01, and **** p < 0.0001.
Phospho Smad2 3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+smad2/Phospho-Smad2+(Ser465%2F467)%2FSmad3+(Ser423%2F425)+Rabbit+mAb/pmc13765516-160-24-25
Average 96 stars, based on 1 article reviews
phospho smad2 3 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc p smad2
Effects of ATL-III on TGF-β1-induced intracellular signaling in primary human corneal keratocytes. Primary human corneal keratocytes were treated with TGF-β1 (10 ng/mL) alone or in combination with ATL-III (50 or 100 µM) for 1 h. Representative Western blot images and corresponding densitometric analyses are shown for ( a ) <t>phosphorylated</t> <t>SMAD2/3</t> (p-SMAD2/3) and total SMAD2/3, ( b ) phosphorylated p38 MAPK (p-p38 MAPK) and total p38 MAPK, ( c ) phosphorylated AMPK (p-AMPK) and total AMPK, ( d ) phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2, and ( e ) phosphorylated NF-κB (p-NF-κB) and total NF-κB. Phosphorylated protein levels were normalized to their corresponding total protein levels and expressed relative to the untreated control group. n = 3 independent experiments. Statistical significance was determined by one-way ANOVA followed by Dunnett’s multiple-comparison test, with the TGF-β1-treated group used as the reference group for treatment comparisons. * p < 0.05, ** p < 0.01, and **** p < 0.0001.
P Smad2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+smad2/Phospho-Smad2+(Ser465%2F467)%2FSmad3+(Ser423%2F425)+Rabbit+mAb/pm42975716-111-25-27
Average 96 stars, based on 1 article reviews
p smad2 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
ABclonal Biotechnology phospho
Effects of ATL-III on TGF-β1-induced intracellular signaling in primary human corneal keratocytes. Primary human corneal keratocytes were treated with TGF-β1 (10 ng/mL) alone or in combination with ATL-III (50 or 100 µM) for 1 h. Representative Western blot images and corresponding densitometric analyses are shown for ( a ) <t>phosphorylated</t> <t>SMAD2/3</t> (p-SMAD2/3) and total SMAD2/3, ( b ) phosphorylated p38 MAPK (p-p38 MAPK) and total p38 MAPK, ( c ) phosphorylated AMPK (p-AMPK) and total AMPK, ( d ) phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2, and ( e ) phosphorylated NF-κB (p-NF-κB) and total NF-κB. Phosphorylated protein levels were normalized to their corresponding total protein levels and expressed relative to the untreated control group. n = 3 independent experiments. Statistical significance was determined by one-way ANOVA followed by Dunnett’s multiple-comparison test, with the TGF-β1-treated group used as the reference group for treatment comparisons. * p < 0.05, ** p < 0.01, and **** p < 0.0001.
Phospho, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+smad2/Phospho-Smad2-S465%2F467+%2B+Smad3-S423%2F425+Rabbit+pAb/pm42888837-91-44-47
Average 95 stars, based on 1 article reviews
phospho - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc p smad2 3
Effects of ATL-III on TGF-β1-induced intracellular signaling in primary human corneal keratocytes. Primary human corneal keratocytes were treated with TGF-β1 (10 ng/mL) alone or in combination with ATL-III (50 or 100 µM) for 1 h. Representative Western blot images and corresponding densitometric analyses are shown for ( a ) <t>phosphorylated</t> <t>SMAD2/3</t> (p-SMAD2/3) and total SMAD2/3, ( b ) phosphorylated p38 MAPK (p-p38 MAPK) and total p38 MAPK, ( c ) phosphorylated AMPK (p-AMPK) and total AMPK, ( d ) phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2, and ( e ) phosphorylated NF-κB (p-NF-κB) and total NF-κB. Phosphorylated protein levels were normalized to their corresponding total protein levels and expressed relative to the untreated control group. n = 3 independent experiments. Statistical significance was determined by one-way ANOVA followed by Dunnett’s multiple-comparison test, with the TGF-β1-treated group used as the reference group for treatment comparisons. * p < 0.05, ** p < 0.01, and **** p < 0.0001.
P Smad2 3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+smad2/Phospho-Smad2+(Ser465%2F467)%2FSmad3+(Ser423%2F425)+Rabbit+mAb/pm42849690-60-66-67
Average 96 stars, based on 1 article reviews
p smad2 3 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc smad3 ser423 425
Effects of ATL-III on TGF-β1-induced intracellular signaling in primary human corneal keratocytes. Primary human corneal keratocytes were treated with TGF-β1 (10 ng/mL) alone or in combination with ATL-III (50 or 100 µM) for 1 h. Representative Western blot images and corresponding densitometric analyses are shown for ( a ) <t>phosphorylated</t> <t>SMAD2/3</t> (p-SMAD2/3) and total SMAD2/3, ( b ) phosphorylated p38 MAPK (p-p38 MAPK) and total p38 MAPK, ( c ) phosphorylated AMPK (p-AMPK) and total AMPK, ( d ) phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2, and ( e ) phosphorylated NF-κB (p-NF-κB) and total NF-κB. Phosphorylated protein levels were normalized to their corresponding total protein levels and expressed relative to the untreated control group. n = 3 independent experiments. Statistical significance was determined by one-way ANOVA followed by Dunnett’s multiple-comparison test, with the TGF-β1-treated group used as the reference group for treatment comparisons. * p < 0.05, ** p < 0.01, and **** p < 0.0001.
Smad3 Ser423 425, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+smad2/Phospho-Smad2+(Ser465%2F467)%2FSmad3+(Ser423%2F425)+Rabbit+mAb/pm41916122-82-15-24
Average 96 stars, based on 1 article reviews
smad3 ser423 425 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc anti psmad2 antibody
Binding properties of PBA-0111 to GARP and GARP/TGF-β1. (A) Increasing concentrations of PBA-0111 were titrated on HEK293T cells overexpressing GARP, GARP/TGF-β1 or empty vector (EV) control, and the binding potency was analyzed by flow cytometry. (B) Increasing concentrations of PBA-0111, an ABBV-151-like antibody, a DS-1055a-like antibody, or an afucosylated isotype control were titrated on L-428 lymphoma cell line, which endogenously expresses GARP/TGF-β1 and the binding potency was analyzed by flow cytometry. Data in (A) and (B) are shown as mean ± standard deviation (SD) and are representative of at least three independent experiments performed in duplicates. (C) Flow cytometry analysis of binding of PBA-0111, DS-1055a-like, or ABBV-151-like antibody to human platelets at 10 µg/mL. Data are expressed as fold change in median fluorescence intensity (MdFI) relative to the afucosylated isotype control, (n=6 independent donors, **p=0.0062, n.s, p=0.06 comparing to PBA-0111, Kruskal-Wallis test). (D) Biolayer interferometry (BLI) binding analysis of PBA-0111 against recombinant extracellular GARP, GARP/TGF-β1, latency associated peptide (LAP), TGF-β1, latent TGF-β1, latent TGF-β2, latent TGF-β3, or GARP paralog leucine-rich repeat-containing protein 15 (LRRC15) at 500 nM. All samples were tested in at least three independent experiments in duplicate. (E) HEK-Blue™ TGF-β reporter assay. Raji GARP/TGF-β1 cells were pre-incubated with the indicated antibodies for 30 minutes and then co-cultured with HEK-Blue™ TGF-β cells. After 48h at 37 °C, SEAP activity was assessed using QUANTI-Blue™ Solution and optical density (OD) measured at 630 nm. Data shown as mean ± SD, n= 9, from 3 independent experiments. Statistical differences were assessed by Kruskal-Wallis test with Dunn´s multiple comparisons versus vehicle or afucosylated isotype control, **p<0.001. (F) Flow cytometry analysis of GARP/TGF-β1 complex formation on Raji-GARP cells. Cells were preincubated with 0.2 ng/mL to 50 µg/mL of PBA-0111, ABBV-151-like antibody, DS-1055a-like antibody, or afucosylated isotype control prior to addition of recombinant latent TGF-β1 at final concentration of 1.5 µg/mL. Complex formation was detected using an anti-LAP antibody. The graph is representative of at least three independent experiments. (G) TGF-β1 signalling was assessed in a Jurkat cell line overexpressing β8-GARP, stimulated with plate-bound anti-CD3 beads and soluble anti-CD28 in the presence of indicated antibodies (20 μg/mL) for 24 h at 37 °C. Cell lysates were analyzed by western blot and densitometric analysis of <t>pSMAD2</t> bands was performed. (H) pSMAD2 band intensities from WB were normalized to the loading control (GAPDH) and then to isotype control,(n= 6 gels, ABBV-151 n=8 samples, 4 MHG-8 and 4 LGH.10.6). Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s multiple comparisons to IgG1.aF control, ***p=0.0002 (ABBV-151, n=8), **p=0.0037 (ADWA11). Statistical significance of PBA-0111 in single comparison to IgG1. aF was performed with Mann-Whitney analysis, p=0.002.
Anti Psmad2 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+smad2/Phospho-Smad2+(Ser465%2F467)+Rabbit+mAb/pmc13627347-92-18-20
Average 96 stars, based on 1 article reviews
anti psmad2 antibody - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc phospho smad2
PTPRC participates in TGF-β/SMAD signaling response representative WB bands for <t>p-SMAD2</t> <t>(Ser465/467),</t> total-SMAD2 (t-SMAD2), and PTPRC across four experimental groups (si-NC / si-PTPRC ± TGF-β1), with GAPDH as the internal reference.
Phospho Smad2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+smad2/Phospho-Smad2+(Ser465%2F467)+Rabbit+mAb/pmc13619489-128-55-57
Average 96 stars, based on 1 article reviews
phospho smad2 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
ABclonal Biotechnology p smad2 3
PTPRC participates in TGF-β/SMAD signaling response representative WB bands for <t>p-SMAD2</t> <t>(Ser465/467),</t> total-SMAD2 (t-SMAD2), and PTPRC across four experimental groups (si-NC / si-PTPRC ± TGF-β1), with GAPDH as the internal reference.
P Smad2 3, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+smad2/Phospho-Smad2-S465%2F467+%2B+Smad3-S423%2F425+Rabbit+pAb/pmc13534946-67-34-36
Average 95 stars, based on 1 article reviews
p smad2 3 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
ABclonal Biotechnology phospho smad2 537
PTPRC participates in TGF-β/SMAD signaling response representative WB bands for <t>p-SMAD2</t> <t>(Ser465/467),</t> total-SMAD2 (t-SMAD2), and PTPRC across four experimental groups (si-NC / si-PTPRC ± TGF-β1), with GAPDH as the internal reference.
Phospho Smad2 537, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+smad2/Phospho-Smad2-S465%2F467+%2B+Smad3-S423%2F425+Rabbit+pAb/10__1016_slash_j__omtn__2026__103120-198-20-45
Average 95 stars, based on 1 article reviews
phospho smad2 537 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
ABclonal Biotechnology psmad2
PTPRC participates in TGF-β/SMAD signaling response representative WB bands for <t>p-SMAD2</t> <t>(Ser465/467),</t> total-SMAD2 (t-SMAD2), and PTPRC across four experimental groups (si-NC / si-PTPRC ± TGF-β1), with GAPDH as the internal reference.
Psmad2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+smad2/Phospho-Smad2-S465%2F467+%2B+Smad3-S423%2F425+Rabbit+pAb/pm42664599-458-37-41
Average 95 stars, based on 1 article reviews
psmad2 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


Effects of ATL-III on TGF-β1-induced intracellular signaling in primary human corneal keratocytes. Primary human corneal keratocytes were treated with TGF-β1 (10 ng/mL) alone or in combination with ATL-III (50 or 100 µM) for 1 h. Representative Western blot images and corresponding densitometric analyses are shown for ( a ) phosphorylated SMAD2/3 (p-SMAD2/3) and total SMAD2/3, ( b ) phosphorylated p38 MAPK (p-p38 MAPK) and total p38 MAPK, ( c ) phosphorylated AMPK (p-AMPK) and total AMPK, ( d ) phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2, and ( e ) phosphorylated NF-κB (p-NF-κB) and total NF-κB. Phosphorylated protein levels were normalized to their corresponding total protein levels and expressed relative to the untreated control group. n = 3 independent experiments. Statistical significance was determined by one-way ANOVA followed by Dunnett’s multiple-comparison test, with the TGF-β1-treated group used as the reference group for treatment comparisons. * p < 0.05, ** p < 0.01, and **** p < 0.0001.

Journal: Molecules

Article Title: Atractylenolide III Attenuates TGF-β1-Induced Myofibroblast Differentiation in Primary Human Corneal Keratocytes

doi: 10.3390/molecules31214040

Figure Lengend Snippet: Effects of ATL-III on TGF-β1-induced intracellular signaling in primary human corneal keratocytes. Primary human corneal keratocytes were treated with TGF-β1 (10 ng/mL) alone or in combination with ATL-III (50 or 100 µM) for 1 h. Representative Western blot images and corresponding densitometric analyses are shown for ( a ) phosphorylated SMAD2/3 (p-SMAD2/3) and total SMAD2/3, ( b ) phosphorylated p38 MAPK (p-p38 MAPK) and total p38 MAPK, ( c ) phosphorylated AMPK (p-AMPK) and total AMPK, ( d ) phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2, and ( e ) phosphorylated NF-κB (p-NF-κB) and total NF-κB. Phosphorylated protein levels were normalized to their corresponding total protein levels and expressed relative to the untreated control group. n = 3 independent experiments. Statistical significance was determined by one-way ANOVA followed by Dunnett’s multiple-comparison test, with the TGF-β1-treated group used as the reference group for treatment comparisons. * p < 0.05, ** p < 0.01, and **** p < 0.0001.

Article Snippet: Following transfer, membranes were blocked with 5% BSA for 30 min and incubated overnight at 4 °C with primary antibodies against the following proteins: phospho-SMAD2/3 (Cellsignaling, catalog no. 8828), SMAD2/3 (Cellsignaling, catalog no. 3102), phospho-AMPK (Cellsignaling, catalog no. 2531), AMPK (Cellsignaling, catalog no. 2532), phospho-NF-κB (Cellsignaling, catalog no. 3033), NF-κB (Cellsignaling, catalog no. 8242), phospho-p38 MAPK (Cellsignaling, catalog no. 9211), p38 MAPK (Cellsignaling, catalog no. 9212), phospho-ERK1/2 (Cellsignaling, catalog no. 9101), ERK1/2 (Cellsignaling, catalog no. 9102), α-SMA (Cellsignaling, catalog no. 14968), GAPDH (Cellsignaling, catalog no. 5174).

Techniques: Western Blot, Control, Comparison

Binding properties of PBA-0111 to GARP and GARP/TGF-β1. (A) Increasing concentrations of PBA-0111 were titrated on HEK293T cells overexpressing GARP, GARP/TGF-β1 or empty vector (EV) control, and the binding potency was analyzed by flow cytometry. (B) Increasing concentrations of PBA-0111, an ABBV-151-like antibody, a DS-1055a-like antibody, or an afucosylated isotype control were titrated on L-428 lymphoma cell line, which endogenously expresses GARP/TGF-β1 and the binding potency was analyzed by flow cytometry. Data in (A) and (B) are shown as mean ± standard deviation (SD) and are representative of at least three independent experiments performed in duplicates. (C) Flow cytometry analysis of binding of PBA-0111, DS-1055a-like, or ABBV-151-like antibody to human platelets at 10 µg/mL. Data are expressed as fold change in median fluorescence intensity (MdFI) relative to the afucosylated isotype control, (n=6 independent donors, **p=0.0062, n.s, p=0.06 comparing to PBA-0111, Kruskal-Wallis test). (D) Biolayer interferometry (BLI) binding analysis of PBA-0111 against recombinant extracellular GARP, GARP/TGF-β1, latency associated peptide (LAP), TGF-β1, latent TGF-β1, latent TGF-β2, latent TGF-β3, or GARP paralog leucine-rich repeat-containing protein 15 (LRRC15) at 500 nM. All samples were tested in at least three independent experiments in duplicate. (E) HEK-Blue™ TGF-β reporter assay. Raji GARP/TGF-β1 cells were pre-incubated with the indicated antibodies for 30 minutes and then co-cultured with HEK-Blue™ TGF-β cells. After 48h at 37 °C, SEAP activity was assessed using QUANTI-Blue™ Solution and optical density (OD) measured at 630 nm. Data shown as mean ± SD, n= 9, from 3 independent experiments. Statistical differences were assessed by Kruskal-Wallis test with Dunn´s multiple comparisons versus vehicle or afucosylated isotype control, **p<0.001. (F) Flow cytometry analysis of GARP/TGF-β1 complex formation on Raji-GARP cells. Cells were preincubated with 0.2 ng/mL to 50 µg/mL of PBA-0111, ABBV-151-like antibody, DS-1055a-like antibody, or afucosylated isotype control prior to addition of recombinant latent TGF-β1 at final concentration of 1.5 µg/mL. Complex formation was detected using an anti-LAP antibody. The graph is representative of at least three independent experiments. (G) TGF-β1 signalling was assessed in a Jurkat cell line overexpressing β8-GARP, stimulated with plate-bound anti-CD3 beads and soluble anti-CD28 in the presence of indicated antibodies (20 μg/mL) for 24 h at 37 °C. Cell lysates were analyzed by western blot and densitometric analysis of pSMAD2 bands was performed. (H) pSMAD2 band intensities from WB were normalized to the loading control (GAPDH) and then to isotype control,(n= 6 gels, ABBV-151 n=8 samples, 4 MHG-8 and 4 LGH.10.6). Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s multiple comparisons to IgG1.aF control, ***p=0.0002 (ABBV-151, n=8), **p=0.0037 (ADWA11). Statistical significance of PBA-0111 in single comparison to IgG1. aF was performed with Mann-Whitney analysis, p=0.002.

Journal: Frontiers in Immunology

Article Title: A fully human afucosylated anti-GARP antibody PBA-0111 drives anti-tumor immunity through combined ADCC induction and TGF-β1 pathway blockade

doi: 10.3389/fimmu.2026.1921265

Figure Lengend Snippet: Binding properties of PBA-0111 to GARP and GARP/TGF-β1. (A) Increasing concentrations of PBA-0111 were titrated on HEK293T cells overexpressing GARP, GARP/TGF-β1 or empty vector (EV) control, and the binding potency was analyzed by flow cytometry. (B) Increasing concentrations of PBA-0111, an ABBV-151-like antibody, a DS-1055a-like antibody, or an afucosylated isotype control were titrated on L-428 lymphoma cell line, which endogenously expresses GARP/TGF-β1 and the binding potency was analyzed by flow cytometry. Data in (A) and (B) are shown as mean ± standard deviation (SD) and are representative of at least three independent experiments performed in duplicates. (C) Flow cytometry analysis of binding of PBA-0111, DS-1055a-like, or ABBV-151-like antibody to human platelets at 10 µg/mL. Data are expressed as fold change in median fluorescence intensity (MdFI) relative to the afucosylated isotype control, (n=6 independent donors, **p=0.0062, n.s, p=0.06 comparing to PBA-0111, Kruskal-Wallis test). (D) Biolayer interferometry (BLI) binding analysis of PBA-0111 against recombinant extracellular GARP, GARP/TGF-β1, latency associated peptide (LAP), TGF-β1, latent TGF-β1, latent TGF-β2, latent TGF-β3, or GARP paralog leucine-rich repeat-containing protein 15 (LRRC15) at 500 nM. All samples were tested in at least three independent experiments in duplicate. (E) HEK-Blue™ TGF-β reporter assay. Raji GARP/TGF-β1 cells were pre-incubated with the indicated antibodies for 30 minutes and then co-cultured with HEK-Blue™ TGF-β cells. After 48h at 37 °C, SEAP activity was assessed using QUANTI-Blue™ Solution and optical density (OD) measured at 630 nm. Data shown as mean ± SD, n= 9, from 3 independent experiments. Statistical differences were assessed by Kruskal-Wallis test with Dunn´s multiple comparisons versus vehicle or afucosylated isotype control, **p<0.001. (F) Flow cytometry analysis of GARP/TGF-β1 complex formation on Raji-GARP cells. Cells were preincubated with 0.2 ng/mL to 50 µg/mL of PBA-0111, ABBV-151-like antibody, DS-1055a-like antibody, or afucosylated isotype control prior to addition of recombinant latent TGF-β1 at final concentration of 1.5 µg/mL. Complex formation was detected using an anti-LAP antibody. The graph is representative of at least three independent experiments. (G) TGF-β1 signalling was assessed in a Jurkat cell line overexpressing β8-GARP, stimulated with plate-bound anti-CD3 beads and soluble anti-CD28 in the presence of indicated antibodies (20 μg/mL) for 24 h at 37 °C. Cell lysates were analyzed by western blot and densitometric analysis of pSMAD2 bands was performed. (H) pSMAD2 band intensities from WB were normalized to the loading control (GAPDH) and then to isotype control,(n= 6 gels, ABBV-151 n=8 samples, 4 MHG-8 and 4 LGH.10.6). Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s multiple comparisons to IgG1.aF control, ***p=0.0002 (ABBV-151, n=8), **p=0.0037 (ADWA11). Statistical significance of PBA-0111 in single comparison to IgG1. aF was performed with Mann-Whitney analysis, p=0.002.

Article Snippet: Protein lysates were run in 4-20% Mini-Protean TGX Gel (BioRad), transferred to membranes followed by overnight incubation with anti-pSMAD2 antibody (Cell signalling technology, 3108L) and subsequent anti-rabbit IgG-HRP (R&D Systems, AF008) for one hour at RT.

Techniques: Binding Assay, Plasmid Preparation, Control, Flow Cytometry, Standard Deviation, Analysis, Fluorescence, Recombinant, Reporter Assay, Incubation, Cell Culture, Activity Assay, Concentration Assay, Western Blot, Comparison, MANN-WHITNEY

PTPRC participates in TGF-β/SMAD signaling response representative WB bands for p-SMAD2 (Ser465/467), total-SMAD2 (t-SMAD2), and PTPRC across four experimental groups (si-NC / si-PTPRC ± TGF-β1), with GAPDH as the internal reference.

Journal: Frontiers in Neurology

Article Title: Transcriptomics-based analysis of muscle injury mechanism mediated by inflammatory imbalance in the Duchenne muscular dystrophy muscle microenvironment

doi: 10.3389/fneur.2026.1905030

Figure Lengend Snippet: PTPRC participates in TGF-β/SMAD signaling response representative WB bands for p-SMAD2 (Ser465/467), total-SMAD2 (t-SMAD2), and PTPRC across four experimental groups (si-NC / si-PTPRC ± TGF-β1), with GAPDH as the internal reference.

Article Snippet: Membranes were blocked with 5% BSA in TBST buffer (500 mM NaCl, 20 mM Tris–HCl, 0.2% Tween) for 1 h, then incubated overnight at 4 °C with primary antibodies against Myh6 (ab185967, Abcam, UK), MyoG (ab124800, Abcam, UK), PTPRC (ab281586, Abcam, UK), COL1A1 (ab260043, Abcam, UK), MMP9 (ab228402, Abcam, UK), and CTGF (ab6992, Abcam, UK), Phospho-SMAD2 (Ser465/467)(#3,108, CST, USA), SMAD2/3 (#3102, CST, USA).

Techniques: